SCHEMBL1978337

SCHEMBL1978337

FC(F)(F)c1ccccc1-c1[c]c2ccccc2cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.38
BACE1 P56817 1/20 0.37
NOTUM Q6P988 1/20 0.36
CYP3A4 P08684 3/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP1A2 P05177 2/20 0.35
ALOX15 P16050 2/20 0.35
MAPK1 P28482 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP2C19 P33261 2/20 0.35
GALR1 P47211 1/20 0.35
TSHR P16473 1/20 0.35
HIF1A Q16665 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP2D6 P10635 1/20 0.35
HPGD P15428 1/20 0.34
AR P10275 1/20 0.34
TRPA1 O75762 3/20 0.34
KMO O15229 1/20 0.34
C1R P00736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3246275 0.77 NPC1 (0.37) BACE1NOTUMALDH1A1CYP1A2MAPK1
SCHEMBL239122 0.74 CYP2A6 (0.37) CYP3A4ALDH1A1CYP1A2HSD17B10TSHR
SCHEMBL3240933 0.73 CYP2A6 (0.39) HSD11B1BACE1ALDH1A1CYP1A2TSHR
SCHEMBL667984 0.73 ALDH1A1 (0.34) BACE1ALDH1A1MAPK1HSD17B10TSHR
SCHEMBL668159 0.73 ALDH1A1 (0.41) CYP3A4ALDH1A1CYP1A2MAPK1HSD17B10
SCHEMBL3249728 0.73 ALDH1A1 (0.34) BACE1CYP3A4ALDH1A1CYP1A2HSD17B10
SCHEMBL4609078 0.73 MAPK1 (0.39) ALDH1A1MAPK1HSD17B10GALR1TDP1
SCHEMBL10501303 0.73 ALDH1A1 (0.39) CYP3A4ALDH1A1CYP1A2ALOX15MAPK1
SCHEMBL5785358 0.72 KIF11 (0.47) BACE1ALDH1A1TSHR
SCHEMBL16697744 0.71 ALDH1A1 (0.35) ALDH1A1MAPK1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011072207-A1 AZOCYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE E. I. DU PONT DE NEMOURS AND COMPANY (US) 2011-06-16 WO disclosed
EP-1167366-B1 AMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2010-05-05 EP disclosed
WO-2008091594-A2 FUNGICIDAL MIXTURES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2008-07-31 WO disclosed
EP-1948649-A2 FUNGICIDAL CARBOXAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2008-07-30 EP disclosed
WO-2007014290-A2 FUNGICIDAL CARBOXAMIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-02-01 WO disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 HSD11B1 413/4885BACE1 1108/4885NOTUM 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.